Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

When are infection risks of blood transfusion tolerable? Towards understanding the ethical views of stakeholders in the blood supply.

Kramer K, Verweij MF, Zaaijer HL.

Vox Sang. 2019 Oct;114(7):658-665. doi: 10.1111/vox.12821. Epub 2019 Jul 5.

2.

Usutu virus infection in Dutch blood donors.

Zaaijer HL, Slot E, Molier M, Reusken CBEM, Koppelman MHGM.

Transfusion. 2019 Sep;59(9):2931-2937. doi: 10.1111/trf.15444. Epub 2019 Jul 4.

PMID:
31270821
3.

Seroprevalence of fourteen human polyomaviruses determined in blood donors.

Kamminga S, van der Meijden E, Feltkamp MCW, Zaaijer HL.

PLoS One. 2018 Oct 23;13(10):e0206273. doi: 10.1371/journal.pone.0206273. eCollection 2018.

4.

Infection Pressure in Men Who Have Sex With Men and Their Suitability to Donate Blood.

van Bilsen WPH, Zaaijer HL, Matser A, van den Hurk K, Slot E, Schim van der Loeff MF, Prins M, van de Laar TJW.

Clin Infect Dis. 2019 Mar 5;68(6):1001-1008. doi: 10.1093/cid/ciy596.

PMID:
30052873
5.

Risk factors for hepatitis E virus seropositivity in Dutch blood donors.

Mooij SH, Hogema BM, Tulen AD, van Pelt W, Franz E, Zaaijer HL, Molier M, Hofhuis A.

BMC Infect Dis. 2018 Apr 13;18(1):173. doi: 10.1186/s12879-018-3078-9.

6.

Phylogenetic analysis reveals three distinct epidemiological profiles in Dutch and Flemish blood donors with hepatitis B virus infection.

van de Laar TJ, Van Gaever VA, Swieten PV, Muylaert A, Compernolle V, Zaaijer HL.

Virology. 2018 Feb;515:243-249. doi: 10.1016/j.virol.2017.12.011. Epub 2018 Jan 8.

7.

Prevention of Transfusion-Transmitted Infections: Dilemmas.

Zaaijer HL.

Front Med (Lausanne). 2017 Dec 12;4:221. doi: 10.3389/fmed.2017.00221. eCollection 2017.

8.

Development and Evaluation of a Broad Bead-Based Multiplex Immunoassay To Measure IgG Seroreactivity against Human Polyomaviruses.

Kamminga S, van der Meijden E, Wunderink HF, Touzé A, Zaaijer HL, Feltkamp MCW.

J Clin Microbiol. 2018 Mar 26;56(4). pii: e01566-17. doi: 10.1128/JCM.01566-17. Print 2018 Apr.

9.

Dynamics of the Immune Response in Acute Hepatitis B Infection.

Stelma F, Willemse SB, Erken R, de Niet A, Sinnige MJ, van Dort K, Zaaijer HL, van Leeuwen EMM, Kootstra NA, Reesink HW.

Open Forum Infect Dis. 2017 Dec 20;4(4):ofx231. doi: 10.1093/ofid/ofx231. eCollection 2017 Fall.

10.

Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients.

Jansen L, Welkers MRA, van Dort KA, Takkenberg RB, Lopatin U, Zaaijer HL, de Jong MD, Reesink HW, Kootstra NA.

Antiviral Res. 2017 Sep;145:87-95. doi: 10.1016/j.antiviral.2017.07.013. Epub 2017 Jul 25.

11.

HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.

Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaaijer HL, Takkenberg RB, Reesink HW.

J Viral Hepat. 2017 Dec;24(12):1107-1113. doi: 10.1111/jvh.12738. Epub 2017 Jul 29.

PMID:
28632898
12.

Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.

de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW.

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584. doi: 10.1016/S2468-1253(17)30083-3. Epub 2017 May 15.

PMID:
28522204
13.

Are there ethical differences between stopping and not starting blood safety measures?

Kramer K, Verweij MF, Zaaijer HL.

Vox Sang. 2017 Jul;112(5):417-424. doi: 10.1111/vox.12525. Epub 2017 May 2.

PMID:
28466467
14.

Meat consumption is a major risk factor for hepatitis E virus infection.

Slot E, Zaaijer HL, Molier M, Van den Hurk K, Prinsze F, Hogema BM.

PLoS One. 2017 Apr 27;12(4):e0176414. doi: 10.1371/journal.pone.0176414. eCollection 2017.

15.

Phylogenetic evidence for underreporting of male-to-male sex among human immunodeficiency virus-infected donors in the Netherlands and Flanders.

van de Laar TJ, Bezemer D, van Laethem K, Vandewalle G, de Smet A, van Wijngaerden E, Claas EC, van Sighem AI, Vandamme AM, Compernolle V, Zaaijer HL.

Transfusion. 2017 May;57(5):1235-1247. doi: 10.1111/trf.14097. Epub 2017 Apr 4.

PMID:
28375576
16.

Stability of BK polyomavirus IgG seroreactivity and its correlation with preceding viremia.

Wunderink HF, van der Meijden E, van der Blij-de Brouwer CS, Zaaijer HL, Kroes AC, van Zwet EW, Rotmans JI, Feltkamp MC.

J Clin Virol. 2017 May;90:46-51. doi: 10.1016/j.jcv.2017.03.015. Epub 2017 Mar 19.

PMID:
28355579
17.

Interpreting and Applying the Precautionary Principle: A Response to Open Peer Commentaries on "The Precautionary Principle and the Tolerability of Blood Transfusion Risks".

Kramer K, Zaaijer HL, Verweij MF.

Am J Bioeth. 2017 Apr;17(4):W4-W6. doi: 10.1080/15265161.2017.1293754. No abstract available.

PMID:
28328382
18.

The Precautionary Principle and the Tolerability of Blood Transfusion Risks.

Kramer K, Zaaijer HL, Verweij MF.

Am J Bioeth. 2017 Mar;17(3):32-43. doi: 10.1080/15265161.2016.1276643.

PMID:
28207362
19.

Cost-effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands.

de Vos AS, Janssen MP, Zaaijer HL, Hogema BM.

Transfusion. 2017 Feb;57(2):258-266. doi: 10.1111/trf.13978. Epub 2017 Jan 31.

PMID:
28144956
20.

Hepatitis E virus infection and hepatic GvHD in allogeneic hematopoietic stem cell transplantation recipients.

Willemse SB, Bezuur DL, Blom P, Kneppers E, Verheij J, Zaaijer HL, Hazenberg MD.

Bone Marrow Transplant. 2017 Apr;52(4):622-624. doi: 10.1038/bmt.2016.327. Epub 2016 Dec 19. No abstract available.

PMID:
27991886
21.

Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection.

van der Valk M, Zaaijer HL, Kater AP, Schinkel J.

J Hepatol. 2017 Jan;66(1):242-243. doi: 10.1016/j.jhep.2016.09.014. Epub 2016 Oct 1. No abstract available.

PMID:
27702641
22.

Hepatitis B Virus Protein X Induces Degradation of Talin-1.

van de Klundert MA, van den Biggelaar M, Kootstra NA, Zaaijer HL.

Viruses. 2016 Oct 19;8(10). pii: E281.

23.

Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants?

Molenaar-de Backer MW, Russcher A, Kroes AC, Koppelman MH, Lanfermeijer M, Zaaijer HL.

J Clin Virol. 2016 Nov;84:19-23. doi: 10.1016/j.jcv.2016.09.004. Epub 2016 Sep 13.

PMID:
27664778
24.

Fluctuation of Viremia in Hepatitis B Virus-Infected Healthcare Workers Performing Exposure-Prone Procedures in the Netherlands.

Raven SF, de Heus B, Wong A, Zaaijer HL, van Steenbergen JE.

Infect Control Hosp Epidemiol. 2016 Jun;37(6):655-60. doi: 10.1017/ice.2016.49.

PMID:
27198603
25.

Seroprevalence of Hepatitis E Virus in Autoimmune Hepatitis Patients in the Netherlands.

van Gerven NM, van der Eijk AA, Pas SD, Zaaijer HL, de Boer YS, Witte BI, van Nieuwkerk CM, Mulder CJ, Bouma G, de Man RA; Dutch Autoimmune Hepatitis Study Group.

J Gastrointestin Liver Dis. 2016 Mar;25(1):9-13. doi: 10.15403/jgld.2014.1121.251.hpe.

26.

Risk Factors and Screening for Trypanosoma cruzi Infection of Dutch Blood Donors.

Slot E, Hogema BM, Molier M, Bart A, Zaaijer HL.

PLoS One. 2016 Mar 7;11(3):e0151038. doi: 10.1371/journal.pone.0151038. eCollection 2016.

27.

Estimating the risk of dengue transmission from Dutch blood donors travelling to Suriname and the Dutch Caribbean.

Oei W, Lieshout-Krikke RW, Kretzschmar ME, Zaaijer HL, Coutinho RA, Eersel M, Jubithana B, Halabi Y, Gerstenbluth I, Maduro E, Tromp M, Janssen MP.

Vox Sang. 2016 May;110(4):301-9. doi: 10.1111/vox.12370. Epub 2016 Jan 14.

PMID:
26765798
28.

In silico prediction of ebolavirus RNA polymerase inhibition by specific combinations of approved nucleotide analogues.

van Hemert FJ, Zaaijer HL, Berkhout B.

J Clin Virol. 2015 Dec;73:89-94. doi: 10.1016/j.jcv.2015.10.020. Epub 2015 Nov 5.

29.

The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.

Willemse SB, Razavi-Shearer D, Zuure FR, Veldhuijzen IK, Croes EA, van der Meer AJ, van Santen DK, de Vree JM, de Knegt RJ, Zaaijer HL, Reesink HW, Prins M, Razavi H.

Neth J Med. 2015 Nov;73(9):417-31.

30.

Incidence and duration of hepatitis E virus infection in Dutch blood donors.

Hogema BM, Molier M, Sjerps M, de Waal M, van Swieten P, van de Laar T, Molenaar-de Backer M, Zaaijer HL.

Transfusion. 2016 Mar;56(3):722-8. doi: 10.1111/trf.13402. Epub 2015 Nov 11.

PMID:
26559806
31.

Rare transmission of hepatitis B virus by Dutch donors with occult infection.

Lieshout-Krikke RW, van Kraaij MG, Danovic F, Zaaijer HL.

Transfusion. 2016 Mar;56(3):691-8. doi: 10.1111/trf.13401. Epub 2015 Nov 11.

PMID:
26559665
32.

Identification of FDA-approved drugs that target hepatitis B virus transcription.

van de Klundert MA, Zaaijer HL, Kootstra NA.

J Viral Hepat. 2016 Mar;23(3):191-201. doi: 10.1111/jvh.12479. Epub 2015 Oct 12.

PMID:
26456011
33.

Two decades of risk factors and transfusion-transmissible infections in Dutch blood donors.

Slot E, Janssen MP, Marijt-van der Kreek T, Zaaijer HL, van de Laar TJ.

Transfusion. 2016 Jan;56(1):203-14. doi: 10.1111/trf.13298. Epub 2015 Sep 9.

PMID:
26355711
34.

An inventory of concerns behind blood safety policies in five Western countries.

Kramer K, Verweij MF, Zaaijer HL.

Transfusion. 2015 Dec;55(12):2816-25. doi: 10.1111/trf.13254. Epub 2015 Aug 30.

PMID:
26331441
35.

Viral metagenomics in drug-naïve, first-onset schizophrenia patients with prominent negative symptoms.

Canuti M, van Beveren NJ, Jazaeri Farsani SM, de Vries M, Deijs M, Jebbink MF, Zaaijer HL, van Schaik BD, van Kampen AH, van der Kuyl AC, de Haan L, Storosum JG, van der Hoek L.

Psychiatry Res. 2015 Oct 30;229(3):678-84. doi: 10.1016/j.psychres.2015.08.025. Epub 2015 Aug 15.

PMID:
26304023
36.

Variability and pathogenicity of hepatitis E virus genotype 3 variants.

Smith DB, Ijaz S, Tedder RS, Hogema B, Zaaijer HL, Izopet J, Bradley-Stewart A, Gunson R, Harvala H, Kokki I, Simmonds P.

J Gen Virol. 2015 Nov;96(11):3255-64. doi: 10.1099/jgv.0.000264. Epub 2015 Aug 14.

37.

Hepatitis B Virus Pregenomic RNA Is Present in Virions in Plasma and Is Associated With a Response to Pegylated Interferon Alfa-2a and Nucleos(t)ide Analogues.

Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL.

J Infect Dis. 2016 Jan 15;213(2):224-32. doi: 10.1093/infdis/jiv397. Epub 2015 Jul 27.

PMID:
26216905
38.

Hepatitis E.

Petrik J, Lozano M, Seed CR, Faddy HM, Keller AJ, Prado Scuracchio PS, Wendel S, Andonov A, Fearon M, Delage G, Zhang J, Shih JW, Gallian P, Djoudi R, Tiberghien P, Izopet J, Dreier J, Vollmer T, Knabbe C, Aggarwal R, Goel A, Ciccaglione AR, Matsubayashi K, Satake M, Tadokoro K, Jeong SH, Zaaijer HL, Zhiburt E, Chay J, Teo D, Chua SS, Piron M, Sauleda S, Echevarría JM, Dalton H, Stramer SL.

Vox Sang. 2016 Jan;110(1):93-130. doi: 10.1111/vox.12285. Epub 2015 Jul 21. No abstract available.

PMID:
26198159
39.

Declining prevalence of hepatitis E antibodies among Danish blood donors.

Holm DK, Moessner BK, Engle RE, Zaaijer HL, Georgsen J, Purcell RH, Christensen PB.

Transfusion. 2015 Jul;55(7):1662-7. doi: 10.1111/trf.13028. Epub 2015 Mar 27.

PMID:
25819381
40.

Chronic hepatitis E resolved by reduced immunosuppression in pediatric kidney transplant patients.

Bouts AH, Schriemer PJ, Zaaijer HL.

Pediatrics. 2015 Apr;135(4):e1075-8. doi: 10.1542/peds.2014-3790. Epub 2015 Mar 9.

41.

Frequent hepatitis E in the Netherlands without traveling or immunosuppression.

Koot H, Hogema BM, Koot M, Molier M, Zaaijer HL.

J Clin Virol. 2015 Jan;62:38-40. doi: 10.1016/j.jcv.2014.11.020. Epub 2014 Nov 20.

PMID:
25542468
42.

The yield of universal antibody to hepatitis B core antigen donor screening in the Netherlands, a hepatitis B virus low-endemic country.

van de Laar TJ, Marijt-van der Kreek T, Molenaar-de Backer MW, Hogema BM, Zaaijer HL.

Transfusion. 2015 Jun;55(6):1206-13. doi: 10.1111/trf.12962. Epub 2014 Dec 15.

PMID:
25494685
43.

No artifact, hepatitis E is emerging.

Zaaijer HL.

Hepatology. 2015 Aug;62(2):654. doi: 10.1002/hep.27611. Epub 2015 Jun 11. No abstract available.

PMID:
25418372
44.

Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.

van Hemert FJ, Berkhout B, Zaaijer HL.

PLoS One. 2014 Sep 2;9(9):e106324. doi: 10.1371/journal.pone.0106324. eCollection 2014.

45.

Predonation screening of candidate donors and prevention of window period donations.

Lieshout-Krikke RW, Zaaijer HL, van de Laar TJ.

Transfusion. 2015 Feb;55(2):373-8. doi: 10.1111/trf.12809. Epub 2014 Aug 7.

PMID:
25130605
46.

Screening of blood donors for chronic Coxiella burnetii infection after large Q fever outbreaks.

Slot E, Hogema BM, Molier M, Zaaijer HL.

Transfusion. 2014 Nov;54(11):2867-70. doi: 10.1111/trf.12749. Epub 2014 Jun 12.

PMID:
24919662
47.

Past and present of hepatitis E in the Netherlands.

Hogema BM, Molier M, Slot E, Zaaijer HL.

Transfusion. 2014 Dec;54(12):3092-6. doi: 10.1111/trf.12733. Epub 2014 May 29.

48.

Human polyomavirus 9 infection in kidney transplant patients.

van der Meijden E, Wunderink HF, van der Blij-de Brouwer CS, Zaaijer HL, Rotmans JI, Bavinck JN, Feltkamp MC.

Emerg Infect Dis. 2014 Jun;20(6):991-9. doi: 10.3201/eid2006.140055.

49.

Estimating the transfusion transmission risk of Q fever.

Oei W, Kretzschmar ME, Zaaijer HL, Coutinho R, van der Poel CL, Janssen MP.

Transfusion. 2014 Jul;54(7):1705-11. doi: 10.1111/trf.12539. Epub 2014 Jan 24.

PMID:
24456030
50.

Screening of post-mortem tissue donors for Coxiella burnetii infection after large outbreaks of Q fever in The Netherlands.

van Wijk MJ, Maas DW, Renders NH, Hermans MH, Zaaijer HL, Hogema BM.

BMC Infect Dis. 2014 Jan 6;14:6. doi: 10.1186/1471-2334-14-6.

Supplemental Content

Loading ...
Support Center